Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical need, with emphasis on cardiovascular and inflammatory indications. Its only marketed product is ARCALYST, a biologic sold in the United States for recurrent pericarditis and certain rare autoinflammatory diseases, while its pipeline includes additional IL-1-related and immunology assets.

11,6 %

88,5 %

8,7 %

+60,1 %

3.79

3.39

— Kiniksa Pharmaceuticals International, plc
%
Commercial biologic product95% ARCALYST, the company's marketed IL-1 trap therapy sold in the U.S. through specialty pharmacies.
Approved rare disease indications5% Approved uses of ARCALYST in recurrent pericarditis, CAPS, and DIRA that drive current sales.
Clinical-stage pipeline0% KPL-387 and related programs being developed for recurrent pericarditis and other inflammatory diseases.
Preclinical assets0% Earlier-stage immunology and cardiovascular programs such as KPL-1161 and other assets.

Kiniksa sells primarily to a select network of third-party specialty pharmacies and logistics partners, which then...

  • Specialty pharmaciesprimary

    They buy ARCALYST for distribution, patient support, and prescription fulfillment, making them the core commercial channel.

  • Physicians and treatment centersprimary

    Cardiologists, rheumatologists, and specialists prescribe ARCALYST for approved rare-disease indications.

  • Patients with recurrent pericarditisprimary

    Patients with painful inflammatory cardiovascular disease who need ongoing biologic treatment.

  • Rare disease patients with CAPS or DIRAsecondary

    Small patient groups using ARCALYST for approved orphan indications.

  • Payors and insurersprimary

    They do not buy the drug directly but determine reimbursement, coverage, and patient access.

The company is headquartered in the United States, with executive offices in Massachusetts and a registered office in...

  • •United States is the only commercial market for ARCALYST
  • •Lexington, Massachusetts is the main operating base
  • •London is the registered office after redomiciliation
  • •UK, Switzerland, Germany, and France house subsidiaries and IP
  • •International footprint supports development and tax structure

Kiniksa's strategy is to expand ARCALYST commercialization in recurrent pericarditis while maintaining access and...

01
Grow ARCALYST in recurrent pericarditisshort-term

It is the company's only commercial product and main revenue driver.

02
Maintain access and reimbursementshort-term

Rare-disease demand depends on coverage, pricing, and specialty pharmacy execution.

03
Advance pipeline diversificationmedium-term

A broader pipeline reduces single-product dependence and supports future growth.

The company is highly dependent on ARCALYST, so any slowdown in uptake, reimbursement pressure, or competitive entry...

high

Dependence on ARCALYST commercialization

The company has one marketed product, so any demand or access disruption can materially affect revenue.

Scope
U.S. rare-disease biologic sales
Materiality
high
high

Third-party manufacturing and supply chain reliance

Commercial and clinical supply are outsourced, and biologic inputs can be scarce or single-sourced.

Scope
Product availability and launch execution
Materiality
high
medium

Reimbursement and payor pressure

Coverage and pricing decisions directly affect patient access and net revenue realization.

Scope
Specialty pharmacy channel and U.S. payors
Materiality
high
medium

Competition in IL-1 and inflammatory diseases

Other drugs may offer more convenient dosing or alternative mechanisms in the same indications.

Scope
Recurrent pericarditis, CAPS, DIRA
Materiality
medium
Revenue recognition and variable consideration
Can move quarterly revenue and gross-to-net margins
Accrued research and development expenses
Affects operating expense timing and comparability
Deferred tax assets and uncertain tax positions
Can affect tax expense and balance sheet valuation allowances

KYNTRA BIO, INC.

KYNB · Pharmaceutical Preparations

ATOSSA THERAPEUTICS, INC.

ATOS · Pharmaceutical Preparations

IONIS PHARMACEUTICALS INC

IONS · Pharmaceutical Preparations

Cinclus Pharma Holding

CINPHA.ST · Health Care

NIKA PHARMACEUTICALS, INC

NIKA · Pharmaceutical Preparations

Journey Medical Corp

DERM · Pharmaceutical Preparations

: 28.4.2026